Form 4: Zimmer Biomet Director Boosts Phantom Stock Holdings

Zimmer Biomet Director Michael J. Farrell acquired 382.263 phantom stock units as part of his deferred compensation plan, increasing his total beneficial ownership to 17,318.948 units.

Summary

• Director Michael J. Farrell acquired 382.263 phantom stock units of Zimmer Biomet Holdings, Inc. (ZBH).
• The transaction occurred on September 30, 2025.
• These units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
• The conversion or exercise price of these derivative securities is 1-for-1, with a stated price of $98.1.
• Following this transaction, Mr. Farrell beneficially owns 17,318.948 phantom stock units.
• This total includes 42.678 phantom stock units accrued on July 31, 2025, through the dividend reinvestment provision of the same plan.
• The units are to be settled in cash in a lump sum within sixty days after Mr. Farrell ceases service as a Director.

Sentiment

Score: 7

Explanation: The accrual of phantom stock units by a director is a positive signal of alignment with shareholder interests, though it is a routine compensation event rather than an open market purchase.

Positives

• Director Michael J. Farrell increased his beneficial ownership of phantom stock units, aligning his interests with shareholders.
• The accrual is part of a structured deferred compensation plan, indicating a stable and predictable compensation mechanism for non-employee directors.

Risks

• The value of the phantom stock units, and thus the eventual cash settlement, is tied to the performance of Zimmer Biomet's common stock.
• Future changes in the company's stock price could impact the final value received by the director.

Future Outlook

The phantom stock units will be settled in cash in a lump sum within sixty days after Michael J. Farrell ceases his service as a Director, linking future compensation to the company's long-term performance.

Industry Context

This transaction reflects a standard practice in executive and director compensation within the medical technology industry, where deferred equity-linked compensation is used to align leadership interests with long-term shareholder value.

Stakeholder Impact

• Shareholders: May view the director's increased holdings as a positive indicator of confidence in the company's future performance and alignment of interests.
• Directors: The deferred compensation plan provides a structured and long-term incentive for non-employee directors.

Next Steps

• Settlement of phantom stock units in cash within 60 days after Michael J. Farrell ceases service as a Director.

Key Dates

Recommendation

This Form 4 filing details a routine accrual of phantom stock units by a director as part of a deferred compensation plan. While it indicates continued alignment of director interests with shareholders, it is not an open market purchase and does not provide new fundamental information to warrant a change from a 'hold' recommendation based solely on this filing.

Keywords

Zimmer Biomet, ZBH, Form 4, Insider Transaction, Phantom Stock Units, Director Compensation, Deferred Compensation, Equity Holdings